|
|
|
Insider
Information: |
Morrison Briggs |
Relationship: |
Director |
City: |
Waltham |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
102,091 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$1,514,965 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
102,091 |
|
|
Total
Value |
$1,514,965 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
7
|
Stock
price went up :
|
2
|
4
|
Stock
price went down : |
0
|
3
|
|
|
|
Gain/Loss Ratio : |
2.0
|
1.3
|
Percentage
Gain/Loss : |
52.4%
|
-14.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
![](../../../Gifs/iconPlus.jpg) |
Syndax Pharmaceuticals Inc |
SNDX |
|
2024-02-07 |
34,836 |
|
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Arvinas Holding Company, Llc |
ARVN |
Director |
2024-05-29 |
29,996 |
|
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Repare Therapeutics Inc. |
RPTX |
Director |
2020-06-23 |
4,800 |
2020-06-23 |
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Codiak Biosciences, Inc. |
CDAK |
Director |
2021-02-17 |
4,761 |
2021-02-17 |
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Werewolf Therapeutics, Inc. |
HOWL |
Director |
2021-04-29 |
15,523 |
|
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Carisma Therapeutics Inc |
CARM |
Director |
2023-03-07 |
12,175 |
2023-03-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
58 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
HOWL |
Werewolf Therapeutics, In... |
Director |
|
2021-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,523 |
|
- |
|
CARM |
Carisma Therapeutics Inc |
Director |
|
2023-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
12,175 |
12,175 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
17,000 |
34,836 |
0 |
- |
|
ARVN |
Arvinas Holding Company, ... |
Director |
|
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,899 |
29,996 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2019-10-10 |
4 |
B |
$5.40 |
$59,400 |
D/D |
11,000 |
31,400 |
0.01 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2023-02-06 |
4 |
OE |
$6.38 |
$337,209 |
D/D |
52,854 |
70,690 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2023-03-13 |
4 |
OE |
$6.38 |
$337,209 |
D/D |
52,854 |
70,690 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-04-10 |
4 |
OE |
$6.38 |
$337,215 |
D/D |
52,855 |
70,691 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-05-09 |
4 |
OE |
$6.38 |
$337,215 |
D/D |
52,855 |
70,691 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-06-09 |
4 |
OE |
$6.38 |
$404,787 |
D/D |
52,855 |
70,691 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2020-11-09 |
4 |
OE |
$7.20 |
$453,154 |
D/D |
62,938 |
109,503 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2020-11-10 |
4 |
OE |
$7.20 |
$125,755 |
D/D |
17,466 |
64,031 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2021-02-08 |
4 |
OE |
$7.20 |
$253,123 |
D/D |
35,156 |
83,492 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2021-09-17 |
4 |
OE |
$7.20 |
$505,886 |
D/D |
70,262 |
118,598 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2021-09-20 |
4 |
OE |
$7.20 |
$360 |
D/D |
50 |
48,386 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-07-01 |
4 |
OE |
$7.20 |
$448,502 |
D/D |
62,292 |
80,128 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-09-14 |
4 |
OE |
$7.20 |
$631,044 |
D/D |
87,645 |
105,481 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-09-15 |
4 |
OE |
$7.20 |
$480,780 |
D/D |
66,775 |
84,611 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-09-16 |
4 |
OE |
$7.20 |
$1,096,226 |
D/D |
125,000 |
70,870 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2019-05-13 |
4 |
B |
$7.29 |
$52,517 |
D/D |
7,200 |
20,400 |
0.01 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2019-05-09 |
4 |
B |
$7.56 |
$99,726 |
D/D |
13,200 |
13,200 |
0.01 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2020-02-04 |
4 |
B |
$8.00 |
$100,000 |
D/D |
12,500 |
43,900 |
0.01 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-07-10 |
4 |
OE |
$8.77 |
$463,538 |
D/D |
52,855 |
70,691 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-08-09 |
4 |
OE |
$8.77 |
$463,538 |
D/D |
52,855 |
70,691 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2021-12-17 |
4 |
OE |
$10.90 |
$383,200 |
D/D |
35,156 |
83,492 |
0 |
- |
|
58 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|